CIK 0001822462 · Non-accelerated filer<br>Smaller reporting company
Foghorn Therapeutics Inc.
Sign in to watch- Ticker
- FHTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-586-3100
- Business address
- 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-26 | Biller Scott Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | Mendelsohn Michael Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | SMITH IAN F Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | Lynch Thomas J. Jr. Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | GILL SIMBA Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | Cole Douglas G. Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | PARSHALL B LYNNE Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-06-26 | Koppel Adam Director | Grant or award · Stock Options (Right to buy) | +16,000 | $5.52 | $88K | 16,000 |
| 2024-05-22 | Flagship Pioneering Inc. 10% owner | Purchase · Pre-Funded Warrants to purchase Common Stock | +1,814,914 | $5.51 | $10.0M | 1,814,914 |
| 2024-05-22 | Flagship Pioneering Inc. 10% owner | Purchase · Pre-Funded Warrants to purchase Common Stock | +1,814,915 | $5.51 | $10.0M | 1,814,915 |
| 2024-04-16 | Humer Kristian Chief Financial Officer | Grant or award · Stock Option (Right to buy) | +275,000 | $6.03 | $1.7M | 275,000 |
| 2024-03-11 | Cavalie Fanny Chief Strategy/Bus Ops Officer | Sale | −11,000 | $6.56 | $72K | 75,992 |
| 2024-01-24 | GOTTSCHALK ADRIAN Chief Executive Officer | Grant or award · Stock Option (right to buy) | +300,000 | $3.06 | $918K | 300,000 |
| 2024-01-24 | Cardama Alfonso Quintas Chief Medical Officer | Grant or award · Stock Option (right to buy) | +60,000 | $3.06 | $184K | 60,000 |
| 2024-01-24 | Cavalie Fanny Chief Strategy/Bus Ops Officer | Grant or award · Stock Option (right to buy) | +80,000 | $3.06 | $245K | 80,000 |
| 2024-01-24 | Costa Carlos Chief People Officer | Grant or award · Stock Option (right to buy) | +90,000 | $3.06 | $275K | 90,000 |
| 2024-01-24 | Bellon Steven F. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +110,000 | $3.06 | $337K | 110,000 |
| 2024-01-24 | LaCascia Michael Chief Legal Officer | Grant or award · Stock Option (right to buy) | +100,000 | $3.06 | $306K | 100,000 |
| 2023-12-08 | SMITH IAN F Director | Grant or award · Stock Option (right to buy) | +26,977 | 26,977 | ||
| 2023-09-11 | Cardama Alfonso Quintas Chief Medical Officer | Grant or award · Stock Options (Right to buy) | +272,000 | $7.57 | $2.1M | 272,000 |
Page 4 of 9 · 177 trades